- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01659021
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Woodville, Australië, 5011
- Queen Elizabeth Hospital
-
-
New South Wales
-
Kogarah, New South Wales, Australië, 2217
- Saint George and Sutherland Hospitals
-
Randwick, New South Wales, Australië, 2031
- Prince of Wales Hospital
-
Westmead, New South Wales, Australië, 2145
- Westmead Hospital
-
-
Queensland
-
Herston, Queensland, Australië, 4029
- Royal Brisbane and Women's Hospital
-
Milton, Queensland, Australië, 4064
- Haematology and Oncology Clinics of Australia at Mater
-
-
South Australia
-
Ashford, South Australia, Australië, 5035
- Ashford Cancer Centre Research
-
-
Victoria
-
Box Hill, Victoria, Australië, 3128
- Box Hill Hospital
-
Melbourne, Victoria, Australië, 3199
- Frankston Hospital
-
-
-
-
-
Antwerpen, België, 2060
- Ziekenhuis Netwerk Antwerpen
-
Brussels, België, 1200
- Cliniques Universitaires Saint Luc
-
Ghent, België, 9000
- Universitair Ziekenhuis Gent
-
Leuven, België, 3000
- Universitaire Ziekenhuis Gasthuisberg
-
-
-
-
-
Winnipeg, Canada, R3E 0V9
- Cancer Care Manitoba
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Cancer Care Manitoba
-
-
Ontario
-
Sudbury, Ontario, Canada, P3E 5J1
- Hopital Regional De Sudbury Regional Hospital (HRSRH) - Regional Cancer Program (RCP)
-
-
Quebec
-
Montréal, Quebec, Canada, H1T 2M4
- Centre Hospitalier Universitaire de Montréal
-
Rimouski, Quebec, Canada, G5L 5T1
- Centre Hospitalier Regional De Rimouski
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 1A5
- Saskatchewan Cancer Agency
-
-
-
-
-
Aalborg, Denemarken, 9100
- Aalborg Hospital
-
Århus, Denemarken, 8000
- Aarhus University Hospital
-
-
-
-
-
Auvergne, Frankrijk, 63000
- CHRU Clermont- Ferrand CHU Estaing
-
Ile-de-france, Frankrijk, 93009
- Centre Hospitalier Universitaire Hopital Avicenne
-
-
Aquitaine
-
Pessac Cedex, Aquitaine, Frankrijk, 33604
- Center Hospitalier Universitaire de Bordeaux
-
-
Ile-de-france
-
Paris Cedex 10, Ile-de-france, Frankrijk, 75010
- Hopital Saint Louis
-
-
Languedoc-Roussillon
-
Perpignan, Languedoc-Roussillon, Frankrijk, 66046
- Centre Hospitalier de Perpignan
-
-
Limousin, Lorraine
-
Vandoeuvre, Limousin, Lorraine, Frankrijk, 54511
- Centre Hospitalier universitaire Nancy
-
-
Midi-pyrenees
-
Toulouse Cedex, Midi-pyrenees, Frankrijk, 31059
- Centre Hospitalier Universitaire Purpan
-
-
-
-
-
Cork, Ierland
- University College Cork
-
Dublin, Ierland, 8
- Saint James's Hospital
-
-
-
-
-
Brzozow, Polen, 36-200
- Szpital Specjalistyczny w Brzozowie
-
Lódz, Polen, 93-510
- Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi
-
Warszawa, Polen, 02-507
- Centralny Szpital Kliniczny MSW
-
Wroclaw, Polen, 50-367
- Samodzielny Publiczny Szpital Kliniczny N1 Klinika
-
-
Malopolskie
-
Kraków, Malopolskie, Polen, 31-501
- Collegium Medicum Uniwersytetu Jagiellonskiego w K
-
-
Pomorskie
-
Slupsk, Pomorskie, Polen, 76-200
- Wojewódzki Szpital Specjalistyczny im. Janusza Kor
-
-
-
-
-
Barcelona, Spanje, 08035
- Hospital Vall D´Hebron
-
Barcelona, Spanje, 08025
- Hospital Clinic I Provincial
-
Madrid, Spanje, 28006
- Hospital Universitario La Princesa
-
Madrid, Spanje, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanje, 28222
- Hospital Puerta de Hierro Majadahonda
-
Murcia, Spanje, 30008
- Hospital Morales Meseguer
-
-
-
-
-
Leeds, Verenigd Koninkrijk, LS9 7TF
- Saint James's University Hospital
-
London, Verenigd Koninkrijk, WC1E 6BT
- University College London
-
London, Verenigd Koninkrijk, NW1 2PG
- University College London
-
Oxford, Verenigd Koninkrijk, OX3 7LE
- Department of Haematology, Cancer and Haematology Centre, Churchill Hospital (Oxford University Hospitals)
-
-
England
-
Birmingham, England, Verenigd Koninkrijk, B9 5ST
- Birmingham Heartlands Hospital
-
Dartford, England, Verenigd Koninkrijk, DA2 8DA
- Darent Valley Hospital
-
Guildford, England, Verenigd Koninkrijk, GU2 7XX
- Royal Surrey County Hospital NHS Trust
-
Manchester, England, Verenigd Koninkrijk, M20 4BX
- Haematology and Transplant Unit
-
-
Norfolk
-
Norwich, Norfolk, Verenigd Koninkrijk, NR4 7UY
- Norfolk and Norwich University Hospital
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope
-
Fresno, California, Verenigde Staten, 93720
- California Cancer Associates for Research and Excellence (cCare)
-
San Diego, California, Verenigde Staten, 92120
- Kaiser Permanente
-
San Luis Obispo, California, Verenigde Staten, 93401
- Coastal Integrative Cancer Care
-
Stanford, California, Verenigde Staten, 94305
- Stanford University Medical Center
-
Vallejo, California, Verenigde Staten, 94589
- Kaiser Permanente Vallejo Medical Center
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80205
- Kaiser Permanente of Colorado
-
Grand Junction, Colorado, Verenigde Staten, 81501
- Saint Mary's Regional Cancer Center
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32256
- Cancer Specialists of North Florida
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Georgia Regents University
-
-
Kentucky
-
Mount Sterling, Kentucky, Verenigde Staten, 40353
- Montgomery Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20817
- Center for Cancer and Blood Disorders, PC
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, Verenigde Staten, 63110-1010
- Washington University Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89169
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Weill Cornell Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45242
- Oncology Hematology Care, Inc.
-
Columbus, Ohio, Verenigde Staten, 43202
- The Ohio State University Medical Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29601
- Upstate Oncology Associates
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, Verenigde Staten, 37203-1781
- Tenessee Oncology, PLLC
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84106
- Utah Cancer Specialists
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98405
- Northwest Medical Specialties
-
-
-
-
-
Luleå, Zweden, 971 80
- Sunderby sjukhus
-
Stockholm, Zweden, 171 64
- Karolinska University Hospital Solna
-
Stockholm, Zweden, 171 76
- Karolinska University Hospital Huddinge
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Adults with previously treated recurrent CLL who have measurable lymphadenopathy
- Require therapy for CLL
- Have experienced CLL progression < 24 months since the completion of the last prior therapy
- Have disease that is not refractory to ofatumumab
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Idelalisib+ofatumumab
Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone. |
150 mg tabletten tweemaal daags oraal toegediend
Andere namen:
Administered intravenously
Andere namen:
|
Actieve vergelijker: Ofatumumab
Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone. |
Administered intravenously
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-Free Survival
Tijdsspanne: Randomization to End of Study (up to 60 months)
|
Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause.
Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.
PFS was analyzed using Kaplan-Meier (KM) estimates.
|
Randomization to End of Study (up to 60 months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Response Rate
Tijdsspanne: Randomization to End of Study (up to 60 months)
|
Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response.
|
Randomization to End of Study (up to 60 months)
|
Lymph Node Response Rate
Tijdsspanne: Randomization to End of Study (up to 60 months)
|
Lymph node response rate was defined as the proportion of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.
|
Randomization to End of Study (up to 60 months)
|
Overall Survival
Tijdsspanne: Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years)
|
Overall survival was defined as the interval from randomization to death from any cause.
Overall survival was analyzed using KM estimates.
|
Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years)
|
Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation
Tijdsspanne: Randomization to End of Study (up to 60 months)
|
Progression-free survival in subgroup of participants with chromosome 17p deletion and/or TP53 mutation was analyzed using KM estimates.
|
Randomization to End of Study (up to 60 months)
|
Complete Response Rate
Tijdsspanne: Randomization to End of Study (up to 60 months)
|
Complete response rate was defined as the percentage of participants who achieve a complete response and maintain their response for at least 8 weeks (with a 1-week window).
|
Randomization to End of Study (up to 60 months)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Gordon MJ, Huang J, Chan RJ, Bhargava P, Danilov AV. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. 2021 Feb;192(4):720-728. doi: 10.1111/bjh.16879. Epub 2020 Jun 29.
- Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4.
- Jones J, Robak T, Wach M, Brown JR, Menter AR, Vandenberghe E, et al. Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 7515]. American Society of Clinical Oncology (ASCO) 52nd Annual Meeting; 2016 02 - 06 June; Chicago, IL.
- Jones JA, Wach M, Robak T, Brown JR, Menter AR, Vanderberghe E, et al. Results of a Phase 3 Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (IDELA) in Combination with Ofatumumab (OFA) for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster 7023]. American Society of Clinical Oncology (ASCO) 51st Annual Meeting; 2015 29 May - 02 June; Chicago, IL.
- Robak T, Jones J, Wach M, Brown JR, Menter AR, Vandenberghe E, et al. Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 213]. 21st Congress of the European Hematology Association (EHA); 2015 09-12 June; Copenhagen, Denmark.
- Robak T, Wach M, Jones J, Owen C, Brown J, Menter A, et al. Results Of A Phase 3 Randomized Controlled Study Evaluating The Efficacy And Safety Of Idelalisib (Idela) In Combination With Ofatumumab (Ofa) For Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster LB598]. 20th Congress of the European Hematology Association (EHA); 2015 11-14 June; Vienna, Austria.
- Flinn I, Kimby E, Cotter FE, Giles FJ, Janssens A, Pulczynski EJ, et al. A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster TPS7131]. American Society of Clinical Oncology (ASCO); 2013 May 31-June 4; Chicago, IL.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Leukemie, B-cel
- Leukemie
- Leukemie, lymfatische, chronische, B-cel
- Leukemie, Lymfoïde
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Ofatumumab
- Idelalisib
Andere studie-ID-nummers
- GS-US-312-0119
- 2012-001236-65 (EudraCT-nummer)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Idelalisib
-
Institut Paoli-CalmettesCHU de ReimsOnbekendAuto-immune cytopenie geassocieerd met chronische lymfatische leukemieFrankrijk
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Gilead SciencesBeëindigdFolliculair lymfoom | Mantelcellymfoom | B-cel chronische lymfatische leukemie | B-cellen-tumoren | Groot B-cel diffuus lymfoom van bot (diagnose)Verenigde Staten
-
Gruppo Italiano Malattie EMatologiche dell'AdultoERIC GroupVoltooid
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Gilead Sciences; Celgene Corporation; Biologics,...VoltooidRecidiverend/refractair mantelcellymfoomVerenigde Staten
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Gilead Sciences; Celgene CorporationVoltooidRecidiverend folliculair lymfoomVerenigde Staten
-
PETHEMA FoundationBeëindigdAcute lymfatische leukemieSpanje
-
Nordic Lymphoma GroupVoltooidDiffuus grootcellig B-cellymfoomDenemarken, Zweden
-
Gilead SciencesVoltooidChronische lymfatische leukemie (CLL) | Acute myeloïde leukemie (AML) | Multipel Myeloom (MM) | Lymfoom, Non-Hodgkin (NHL)Verenigde Staten
-
Gilead SciencesVoltooidChronische lymfatische leukemieVerenigde Staten, Frankrijk, Verenigd Koninkrijk, Duitsland, Italië
-
University of Maryland, BaltimoreGilead Sciences; University of Miami Sylvester Comprehensive Cancer CenterActief, niet wervendFolliculair lymfoom | B-cel lymfoom | Waldenström Macroglobulinemie | Marginale zone lymfoom | Lymfoplasmacytisch lymfoom | Non-Hodgkin lymfoom | Klein lymfocytisch lymfoom | Getransformeerd lymfoom | Indolent lymfoomVerenigde Staten